Rivus Capital, the investment company of entrepreneur Michael Peter, has taken over a majority stake in Andramed GmbH, based in Reutlingen. Michael Peter, as the founder and sole shareholder of Rivus Capital, pursues a long-term, entrepreneurially-oriented approach with his investments. Andramed specialises in the development, production, and distribution of innovative medical devices for interventional paediatric cardiology. The company provides solutions for the treatment of congenital heart defects in children, toddlers, and infants. The company's products are used in more than 50 countries.
Michael Peter stated that Andramed combines high medical utility with technological expertise and exceptional specialisation. He emphasised that his aim is not merely to provide capital to companies, but to support them in their development as a long-term entrepreneurial partner. The joint strategy with Andramed's management aims to expand international presence, drive innovation, and sustainably strengthen the Reutlingen site.
Specialised Medical Technology and Vertical Integration
For over 20 years, Andramed has been developing specialised solutions for paediatric cardiology. The company's products support doctors in the gentle and effective treatment of complex procedures for congenital heart defects in children, toddlers, and infants. Andramed possesses an established and patented portfolio that includes stents, balloon catheters, and snares. Furthermore, patient-specific special solutions are developed and manufactured in close collaboration with leading clinics and medical experts.
A core competence of the Reutlingen company lies in its high depth of development and manufacturing. Andramed covers the entire value chain internally, from development and prototyping through certified manufacturing to regulatory approval. Andramed also makes this expertise available to external partners as a development and manufacturing service provider.
Continuity and Growth Strategy
As part of the transaction, Andramed founder Heinz Schade will step down from the management board. His daughter Jessica Schade, who is already a managing director, will continue to lead the company and, together with Rivus Capital, shape the next growth phase. The joint strategy focuses on international expansion, the targeted expansion of the product portfolio, and the extension of manufacturing capacities at the Reutlingen site. A promising pipeline of new product developments offers additional growth potential. Furthermore, it is planned to further develop Andramed through targeted acquisitions.
Michael Peter stated that he sees great potential in Andramed to expand its strong position in a highly specialised international market. He emphasised the long-term thinking, whose goal is to preserve Andramed's entrepreneurial independence and innovative strength while creating the conditions for the next stage of development. The partnership between Andramed and Rivus Capital is intended to sustainably strengthen the company's technological competence and international presence, to enable more children, toddlers, and infants worldwide to access innovative treatment options in paediatric cardiology.
